Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
TREATMENT OF DERMATOMYOSITIS WITH METHOTREXATE
Autore:
ZIEGLSCHMIDADAMS ME; PANDYA AG; COHEN SB; SONTHEIMER RD;
Indirizzi:
UNIV TEXAS,SW MED CTR,DEPT DERMATOL,5323 HARRY HINES BLVD DALLAS TX 75235 UNIV TEXAS,SW MED CTR,DEPT DERMATOL DALLAS TX 75235 UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED DALLAS TX 75235 ST PAUL RAMSEY MED CTR,DIV RHEUMATOL DALLAS TX 00000
Titolo Testata:
Journal of the American Academy of Dermatology
fascicolo: 5, volume: 32, anno: 1995,
parte:, 1
pagine: 754 - 757
SICI:
0190-9622(1995)32:5<754:TODWM>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
STEROID-RESISTANT DERMATOMYOSITIS; POLYMYOSITIS; THERAPY; CHLORAMBUCIL; GUIDELINES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
26
Recensione:
Indirizzi per estratti:
Citazione:
M.E. Zieglschmidadams et al., "TREATMENT OF DERMATOMYOSITIS WITH METHOTREXATE", Journal of the American Academy of Dermatology, 32(5), 1995, pp. 754-757

Abstract

Background: No published data exist on the incidence of liver fibrosis in patients with dermatomyositis treated with methotrexate. Objective: Our purpose was to examine the efficacy, steroid-sparing potential,and side effects of methotrexate in patients with dermatomyositis andto report liver biopsy results in four patients. Methods: A retrospective review of all cases of dermatomyositis treated with methotrexate in a dermatology and rheumatology referral practice was conducted.Results: Of the 10 cases reviewed, seven were of dermatomyositis whereas three were of amyopathic dermatomyositis (ADM). Nine patients received oral methotrexate. One patient received intravenous methotrexate. Improvement of cutaneous disease occurred in seven (100%) of the patients with dermatomyositis and in two (66%) of those with ADM; myositis improved in four (57%) of the patients with dermatomyositis. The initial prednisone dose was halved after an average of 18 weeks of methotrexatetherapy in the patients with dermatomyositis and 13 weeks in the patients with ADM. Methotrexate-related side effects occurred in six (86%)of the patients with dermatomyositis and in one (33%) of the patientswith ADM. Of the four patients who had liver biopsies, two (50%) showed mild hepatic fibrosis, resulting in discontinuation of the drug. Both patients in whom fibrosis developed had preexisting steroid-induceddiabetes mellitus. Conclusion: Although methotrexate is an effective treatment for dermatomyositis, side effects are common. Patients with diabetes mellitus should be closely monitored for toxic effects on theliver.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 06:27:40